Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.

THE GAMECHANGER: Insulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.

Upon successful completion of this course, learners should be able to:
1. Explain the chemical and structural changes that make icodec different from other basal insulins
2. Discuss the results of the meta-analysis about insulin icodec

Jen Moulton, RPh
President + Founder
CEimpact

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Jen Moulton has no relevant financial relationships with ineligible companies to disclose.

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: January 29, 2024
Planned Expiration Date: January 29, 2025

Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.